Clinical trial hotspots revealed in new heatmap and data analysis
The new independent report Commercial clinical trials in the UK: the Lord O’Shaughnessy review highlights the decline of clinical trials in the UK and importance of restoring the UK’s leading position.
Lord O’Shaughnessy said in the review:
We can do so much better than we currently are, and everything I have heard from clinicians, patients, researchers, NHS bodies, industry and others during the course of this review reveals a strong desire to regain our world-leading position in this area. I am confident it is possible, which is why I have proposed that the government should aim to double the numbers of people taking part in commercial clinical trials in the next 2 years, and double it again by 2027.
Indeed, it is more important than ever to examine patterns and trends in clinical trials, and to develop resources that facilitate the location of clinical trials in the UK.
Commercial Clinical Trials London & UK data analysis & heatmap
New data analysis, developed as part of a collaboration between UK Advanced Therapies and MedCity, spotlights centres of expertise in London and the UK for commercial clinical trials.
In light of the concerns around clinical trial activity, it is significant that the new data highlights the consistent strength of London for life sciences clinical trials. The research, together with our new heatmap of clinical trial activity, illustrate London’s position as a hotspot for commercial clinical trials, with advanced therapies (in particular, oncology) trials being a standout area of expertise.
The research and heatmap have been developed as a resource for international pharmaceutical companies planning clinical trials, reflecting data from the last 10 years of commercial clinical trial activity across the UK.
The Clinical Trials map allows analysis of our UK portfolio of trials in fields relevant to Cell and Gene Therapies such as oncology. It is an invaluable tool not only for examining trends but also for setting out strategies and developing collaborative work.
Dr Francesca Gliubich, Director of UK Advanced Therapies
There is no doubt that the UK has great strengths in having NHS
infrastructure to conduct clinical trials, leading science and research capabilities and a forward thinking regulatory environment. What is sometimes missing is visibility of where these clinical trials are conducted and where that expertise is.
One of MedCity’s roles is to support the navigation of our complex ecosystem. This report and heatmap helps researchers, innovators and investors to identify areas of opportunity. London’s strength in advanced therapies clinical trials is a superb exemplar.
Neelam Patel, CEO, MedCity